What's hot
View all perspectives
Nelly ZIADE 🍀 Nellziade
3 months ago
Diagnostic delay in #SpA
🔹️Data from the @Official_ASAS
Study
🔹️4339 patients
🔹️Delay was 6.6 years
🔹️Longer in axSpA and IBD-SpA, shorter in PsA and pSpA
🔹️Associated with type of initial symptoms (shorter in peripheral)
POS0909 #EULAR2025
@rheumnow https://t.co/3BMYFxbKiq
Adela Castro AdelaCastro222
3 months ago
LDCT to assess disease progression in early axSpA:
-Data from SPACE cohort 67 pts (>50% male,>80% hLAB27+)
- LDCT at baseline and 2 years apart.
-Overall 22% pt with net disease progression.
-Spine progression most frequent on thoracic spine.
-Good reliability in assessing https://t.co/M2jkDusD41
Jiha Lee JihaRheum
3 months ago
🎯 Early MTX hits the mark — but only in ACPA-negative.
In TREAT EARLIER, 1 year of MTX led to lasting benefits at 5 years:
➖ Less RA
➖ Better function
❌ No benefit in ACPA+
Abstract#OP0324 @RheumNow #EULAR2025
Janet Pope Janetbirdope
3 months ago
#ANCA #vasculitis is not created equally
REVEAL cohort 588 ANCA
Initial & 12 months #BVAS (activity index)
mean ⬇️BVAS over 1 yr in all groups
#GPA #MPA #eGPA
5yr survival not = over time
⬆️survival in eGPA & GPA vs MPA
#POS0329 #EULAR2025 @RheumNow @eular_org https://t.co/cUKytqNZnS
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#POS0325 Immunosuppressant-free is not only confined to CAR-T. Our cohort study in #SLE: 20% patients were “Super-Responder” (>3yrs response) inc. 7% IS-free after one Rituximab cycle. Non-European, APS & shorter disease duration predicted super-response @RheumNow https://t.co/nPIYpGoynR
David Liew drdavidliew
3 months ago
Is RA just one disease?
No, & increasingly more efforts to subgroup RA on diff levels
Simple approach - derived phenotypes map (independent of ACPA):
- to broad histopath
- to MTX response
Omics is good, but still need to do the simple stuff better!
#EULAR2025 OP0328 @RheumNow https://t.co/a8Vl7Kcjso
Is there a higher risk of cancer that comes with the disease? Or with the treatments? So many confounding parameters, such as disease duration, disease state, and disease activity come into play. A promising session explored comorbidities in Rheumatoid Arthritis, in particular cancer and cardiovascular events. Here are my takeaways.
Day 2 was a full agenda for those attending EULAR 2025 in Barcelona with sessions on the management of RA, Behcets, Lupus and Hand Osteoarthritis. Clinical overviews on MAS, Ehlers-Danlos, Difficult to treat RA and PsA offered a wide variety of options to rheumatologists. Here are a few interesting presentations from today.
Antoni Chan MD (Prof) synovialjoints
3 months ago
In axSpA patients with persistent pain, digital behavioral therapy (ACT-app) improved MPI pain-related life interference (β −0.36, 95% CI −0.73 to 0.01) and affective distress (β −0.40, 95% CI −0.84 to 0.003) vs standard of care (SOC). 43% completed full program. NPS 5.8. https://t.co/T6i9jkjcoU
Antoni Chan MD (Prof) synovialjoints
3 months ago
In AS (n=91,493), D2T defined as ≥2 b/tsDMARD classes plus elevated CRP. Risk factors: HLA-B27+ (OR 1.30), obesity (OR 1.20), depression (OR 1.22). D2T group had higher CRP (55.7 mg/L), BMI (31.1), and more EAMs (IBD, psoriasis, uveitis). Female predominance (56.9%)Abstract https://t.co/EHCt5wq4ot
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#OP0199 Validation of effective & safe HCQ blood levels monitoring (750-1150ng/mL) to guide optimal dose. Particulary important in those with CKD Stage =>3 as considered high risk of toxicity. Next steps: wider availability & cost-effectiveness analysis @RheumNow https://t.co/WoVFolrmPA
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#OP0200 Which social determinant of health in Europe affect #SLE outcomes so that these can be improved? Registry in Sweden showed factors associated with damage/mortality:
- Lower income & education,
- No partner
- On sick leave/disability benefits
@RheumNow https://t.co/hgEfJzoqNg
Md Yuzaiful Md Yusof Yuz6Yusof
3 months ago
#EULAR2025 Abstr#OP0201 Achieving treatment targets (LLDAS and/or DORIS) is more prognostically important. In Phase 3 RCT, compared with PBO+SOC, Dapirolizumab+SOC resulted in higher rates of achievement and time in LLDAS and DORIS. LLDAS plateud after WK28 in PBO+SOC @RheumNow https://t.co/3Zd3jjx984
Poster Hall